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Background: Over half of the patients were diagnosed with colorectal cancer after 70 years of age. The choice of
the most suitable chemotherapy strategy is the major challenge for elderly patients. Previous trials indicated that
elderly patients with stage II/III colorectal cancer obtained no significant benefits from oxaliplatin-based adjuvant
chemotherapy. Therefore, single-agent oral capecitabine is regarded as an effective alternative with retained efficacy
and improved flexibility. However, the optimal dose of capecitabine for elderly patients remains controversial. Recent
studies have adopted a low-dose strategy (1,000 mg/m2) for elderly patients, but the long-term efficacy of this strategy
has not been identified so far. Thus, we designed this trial to investigate non-inferiority of the lower-dose strategy of
capecitabine compared with the approved-dose strategy for adjuvant chemotherapy of elderly patients with stage II/III
colorectal cancer.
Methods: LC-ACEC (Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal
Cancer) is a prospective, randomized, open-label, non-inferiority phase III clinical trial including 926 eligible patients.
Patients will be randomly assigned to receive a capecitabine adjuvant chemotherapy strategy of lower dose
(1,000 mg/m2 twice daily on days 1 to 14 of every 21 days) or approved dose (1,250 mg/m2 twice daily on days 1
to 14 of every 21 days). The primary outcome is 3-year disease-free survival. Secondary outcomes include 3-year
overall survival, toxic and side effects during treatment, completion rate, and quality of life.
Discussion: This is the first randomized trial to evaluate the efficacy and safety of a low-dose strategy of capecitabine
in adjuvant chemotherapy of elderly patients with stage II/III colorectal cancer, and the results are believed to provide
new evidence on the treatment of elderly patients with colorectal cancer.
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In Western countries, the incidence of colorectal cancer
(CRC) peaked in patients more than 70 years old [1]. As
for Chinese patients with CRC, the median age of diag-
nosis was 50 in the 1980s; however, it had reached 58 in
2005 and has been rising recently [2]. Limited by age-
related organ function decline and comorbid conditions,
elderly patients show impaired physical and mental tol-
erance for cancer treatment, such as chemotherapy.
Generally, stage II (T3-4N0M0) and stage III (TanyN1-2M0)
colorectal carcinoma, the most common CRC in Chinese
patients [3], can be resected by surgery. Additional adjuvant
chemotherapy could significantly improve survival of stage
II/III CRC patients compared with surgery alone [4]. Re-
sults of a pooled analysis including 3,351 CRC cases indi-
cated that, in view of both efficacy and safety, elderly
patients (more than 70 years old) achieved the same bene-
fits from adjuvant chemotherapy as younger patients [5].
According to the large-scale retrospective analysis of the
Adjuvant Colon Cancer Endpoints (ACCENT) database,
patients at least 70 years of age accounted for only 17.1 %
of all cases [6], which was much lower than expected.
Therefore, improving the acceptance and completion rate
of adjuvant chemotherapy for elderly patients with stage II/
III CRC has become imperative.
The oxaliplatin-based combination chemotherapy (Folfox,
Xelox) has been widely recommended recently [7]. How-
ever, the ACCENT analysis reported that adding oxaliplatin
extended no significant benefits for elderly patients [6],
suggesting that single-agent chemotherapy might be pre-
ferred for those patients. Capecitabine (Xeloda; Hoffmann-
La Roche Inc., Nutley, NJ, USA), as the oral prodrug of 5-
fluorouracil (Fu) recommended by global guidelines [8–10],
has been proven to be at least equivalent to Fu bolus and
intravenous Fu plus leucovorin (Lv) adjuvant chemotherapy
for CRC [11–13] and to haveenhanced flexibility and com-
pliance [12, 14]. Currently, the approved dose of capecita-
bine is 1,250 mg/m2 twice a day (bid) on days 1 to 14 of
every 21 days [15], but the optimal dose for various groups
of patients characterized by different ethnicity and age re-
mains controversial. Moreover, although only relatively
healthy elderly patients—that is, age of not more than
75 years and Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of not more than 1—were eventu-
ally included, the X-ACT (Xeloda in Adjuvant Colon
Cancer Therapy) trial (m66001) found that 51 % of those
patients undergoing 1,250 mg/m2 strategy required dose re-
duction to complete the whole chemotherapy, significantly
more than younger patients, indicating that the approved
dosage might be an overdose for elderly patients [16]. A
previous non-randomized comparative analysis by Bajetta
et al. reported that the completion rate (with no dose
reduction) of a low-dose strategy of capecitabine (1,000
mg/m2 bid) was higher than the approved strategy (95 %versus 70 %), further concluding that 1,000 mg/m2 could be
applied as a new recommended strategy for elderly patients
with breast cancer [17]. The AVEX (bevacizumab plus
capecitabine versus capecitabine alone in elderly patients
with previously untreated metastatic colorectal cancer)
trial (ClinicalTrials.gov identifier NCT00484939) in 2013
adopted the 1,000 mg/m2 low-dose strategy for metastatic
CRC patients at least 70 years old [18]. However, it is well
established that patients of different tumor stage have sig-
nificantly different clinical characteristics. A recent single-
arm study has verified feasibility of this starting dose at
1,000 mg/m2 bid for elderly (at least 70 years old) patients
with stage II/III colon cancer [19] but has not produced re-
sults of efficacy. Thus far, however, no data on the optimal
dose of capecitabine applied in elderly patients with stage
II/III CRC have been available. Furthermore, the long-term
efficacy of this 1,000 mg/m2 strategy, though widely used in
elderly patients with cancer, has not been identified in com-
parison with the approved strategy.
For more individualized evidence guiding CRC treat-
ment, we designed a non-inferiority randomized trial to
identify the efficacy and safety of the low-dose capecitabine
strategy (1,000 mg/m2 bid) for adjuvant chemotherapy of
elderly (at least 70 years old) patients with stage II/III CRC.
Methods
Study objective
The primary objective of the LC-ACEC (Low-dose Capecit-
abine Adjuvant Chemotherapy for Elderly Patients With
Stage II/III Colorectal Cancer) trial is to investigate the
non-inferiority of the efficacy of low-dose capecitabine
(1,000 mg/m2 bid) applied in adjuvant mono-chemotherapy
for elderly patients with stage II/III CRC. Furthermore, we
aim to compare the toxic and side effects, completion rate,
and quality of life (QoL) of the low-dose strategy with the
approved-dose strategy (1,250 mg/m2 bid).
Study design and setting
This is a prospective, randomized, open-label, non-
inferiority phase III clinical trial with two parallel groups.
Patients in the low-dose group receive 1,000 mg/m2 bid
capecitabine postoperatively; accordingly, patients in the
approved-dose group receive 1,250 mg/m2 bid capecita-
bine. Fig. 1 illustrates the overall flow of participants in
this trial.
Our trial began in January 2015 in the West China
Hospital (WCH) of Sichuan University in China and is
expected to end in 2023.
Ethical considerations
This trial protocol is approved by the Biological and
Medical Ethics Committee of WCH (reviewed in 2014
as #74) and has been registered at ClinicalTrials.gov
(identifier NCT02316535). All of the eligible participants
Fig. 1 Overall flowchart of the LC-ACEC (Low-dose Capecitabine
Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal
Cancer) trial
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tential risks and benefits of interventions in each group;
only patients who are willing to provide written in-
formed consent can be enrolled in the trial. The results
of the trial will be reported in accordance with the
CONSORT (Consolidated Standards of Reporting Trials)
statement.
Study population
The selection criteria of our trial are as follows:
Inclusion criteria
(1) With written informed consent
(2) Pathologically identified carcinoma of colon
and rectum(3) pT3-4NanyM0 or pTanyN +M0 (stage II/III)
(4) Age of at least 70 years to not more than 90 years
(5) Underwent R0 resection (that is, no residue tumor)
(6) ECOG PS of not more than 2
(7) Life expectancy of at least 3 months
(8) Initiation of adjuvant therapy within 12 weeks
after surgery [20].
Exclusion criteria
(1) With other types of malignances within
the past 5 years
(2) Creatinine clearance of not more than
50 mL/minute
(3) History of neoadjuvant chemotherapy
(4) In anticoagulant therapy
(5) History of angina pectoris, congestive heart failure,
or myocardial infarction within the past 12 months
(6) History of other antineoplastic drugs
(7) History of substance abuse
(8) With other contraindications for chemotherapy
(for example, thrombocytopenia, ongoing infection,
and impaired liver function).
Randomization and blinding
All participants fulfilling the inclusion criteria will be
randomly allocated into either the low-dose or the
approved-dose group. We use a computer-generated
blocked randomization sequence with the block size of
four according to the previous published trial conducted
in WCH [21]. Patients are randomly assigned by stratifi-
cation of disease stage (stage II or III) and primary
tumor site (colon or rectum). To achieve allocation con-
cealment, opaque envelopes with sequential numbers are
adopted to seal the assignment and are accessible only
for investigators not involved with this trial. After enroll-
ment of each patient, the envelope is sent to an inde-
pendent investigator, who is not involved in patient
evaluation, to assign participants to either the low-dose
or the approved-dose group. This is an open-label trial;
thus, patients, investigators, and data analysts are aware
of the group assignment.
Intervention
About 4 to 8 weeks after surgery [20], patients in the low-
dose group will take oral capecitabine after breakfast and
dinner at the dose of 1,000 mg/m2 bid, and patients in the
approved-dose group will receive the dose of 1,250 mg/m2
bid. Each treatment cycle consists of 14 days of capecita-
bine administration and then 7 days of rest.
Colon cancer patients in both groups are supposed to
take eight circles of treatment in total (24 weeks) [22].
Eight circles of treatment will also apply to rectal cancer
patients who had neoadjuvant radiotherapy (regimen 1
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radiotherapy, we defined high-risk patients who need
concomitant radiochemotherapy (RCT) as patients with
positive circumferential resection margin (CRM+) or
with lymph node metastasis (N+), and they will receive a
total of five circles of chemotherapy [13]. The RCT
serves as the third circle and lasts about 6 weeks [13].
During the RCT period, the irradiation dose is 45 Gy/25
fractions, and the capecitabine dose is reduced to
800 mg/m2 bid [23] (regimen 2 in Fig. 2). According to
the toxic events, the dose of capecitabine will be
adjusted following the drug instruction of Xeloda® [15].
Any patients who have intolerable toxic or side effects
will discontinue the medication.
Outcomes
Primary outcome
The primary outcome of the LC-ACEC trial is 3-year
disease-free survival (DFS), which is calculated from the
date of randomization to whichever of the following events
occurs first in 3 years: local recurrence, metastasis, death
from any causes, or development of other malignances.
Secondary outcome
Several secondary outcomes are adopted in this trial. In
addition to the primary outcome of 3-year DFS, the 3-year
overall survival is calculated from the randomization to
the date of death from any causes. Toxic and side effects
during adjuvant chemotherapy will be closely observed
and evaluated by using National Cancer Institute Com-
mon Toxicity Criteria (NCI-CTC) version 2.0. Based on
the toxic and side effects, we will keep every record of
modification or discontinuance of capecitabine and calcu-
late the completion rate of the treatment as one of the key
secondary outcomes. Moreover, QoL data are recorded by
using a Chinese translation of European Organisation for
Research and Treatment of Cancer Core QoL Question-
naire C30 (EORTC QLQ-C30) [24].Regimen 1
Regimen 2
Week
Regimen 1: patients with neoadjuvant radiotherapy, low risk rectal cancer pati
Regimen 2: high risk rectal cancer patients with no neoadjuvant radiotherapy 
1 2 3 4 5 6 7 8 9 10 11





Fig. 2 Treatment regimen. RCT, radiochemotherapyFollow-up and data collection
The medical history and physical examination will be
taken immediately at the outpatient clinic. After patients
pass the selection procedure and sign the informed con-
sent form, a series of investigations, including complete
blood test (for example, blood cell count and blood
chemistry), tumor markers of carcinoembryonic antigen
(CEA) and carbohydrate antigen 19-9 (CA 19-9), total
abdominal computed tomography (CT) scan, and chest
radiograph, will be scheduled. It is worth mentioning
that before every circle of chemotherapy, renal function
of each participant will be monitored and evaluated by
calculating the creatinine clearance. When participants
finish every circle of chemotherapy, investigators will as-
sess the toxic and side effects by using NCI-CTC and
record any modification or discontinuation of capecita-
bine. In view of possible compromised compliance of
elderly patients, returned medication will be checked at
the clinic, and patients who discontinue the treatment
for more than 1 week (except for toxic effects) will be
withdrawn from this trial. When the whole treatment is
over, patients will come to the hospital for a check-up
every 3 months in the first 2 years and every 6 months
afterward. Each time, the complete blood test, tumor
markers, total abdominal CT scan, chest radiograph, and
rectal examination will be conducted to help oncologists
verify the possible local recurrence and metastasis, and
the QoL questionnaire will be filled. We will follow up
patients on a corresponding timeline at the clinic or by
phone. All the data of each patient will be recorded in a
case report form (CRF) in time.
Safety and data monitoring
An independent data and safety monitoring board
(DSMB) composed of oncologists, gastrointestinal sur-
geons, and statisticians is responsible for reviewing trial
data, including adverse events (AEs) and drop-outs, at
least twice a year. If any unexpected AEs happen or anyents or colon cancer patients
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Chinese database and most authors reported, members
of the DSMB will consider early closure of this trial ac-
cording to relevant Chinese laws and regulations. AEs in
this trial are evaluated by using NCI-CTC as a secondary
outcome. Severe adverse events (SAEs) in this trial
include death, disability, and prolonged hospitalization.
Both AEs and SAEs will be recorded in CRFs and the
DSMB will be informed within 24 hours.
Sample size and statistics
The LC-ACEC trial aims to identify the non-inferiority
of 3-year DFS of patients in the low-dose capecitabine
adjuvant chemotherapy group versus the approved-dose
group. We assumed that a background 3-year DFS was
60 % and predefined the non-inferiority margin of the haz-
ard ratio (HR) as 1.30. When 456 events of the primary
endpoint 3-year DFS occur, the efficacy analysis will be
conducted. We chose a statistical power of 0.80 and a sig-
nificance level of 0.05 (two-sided). Given the 10 % drop-
out for elderly patients, the calculation yielded a sample
size of 926 patients (463 in each arm) [11, 25].
The intention-to-treat analysis will be applied with all
patients who undergo randomization in this trial. With re-
gard to survival data, HRs with 95 % confidence intervals
(CIs) will be presented by Kaplan-Meier survival esti-
mates. Additionally, Cox proportional HRs with 95 % CIs
will be calculated on the basis of subgroups of different
characteristics (that is, age, sex, stratum, and Charlson co-
morbidity index), which can identify the influence of com-
peting risk factors for the outcome event. For the primary
outcome of 3-year DFS, the non-inferiority will be con-
cluded if the upper limit of the 95 % CI is not more than
1.30 (predefined non-inferiority margin). As for other
outcomes, proportions will be compared by using chi-
squared test, and continuous data will be analyzed by t
test. All the statistical analyses will be conducted by using
SPSS version 20 software (SPSS, Inc., Chicago, IL, USA).
Discussion
It is well established that age is a major risk factor for
CRC. According to available statistics, over half of patients
with CRC are at least 70 years old, and approximately
43 % of them are at least 75 years old [26]. For stage II/III
CRC, adjuvant chemotherapy has been demonstrated to
significantly improve survival, and these benefits are not
influenced by age [5]. Therefore, there is no doubt that
adjuvant chemotherapy should be applied for elderly
patients with stage II/III CRC. In reality, however, elderly
patients are generally undertreated with chemotherapy be-
cause of relatively poor health, and this resulted in a lower
participation rate of elderly patients in previous large-
scale studies [6] and compromised applicability of those
conclusions to elderly patients. Currently, relatively littleis known about adjuvant chemotherapy specifically for
elderly patients with stage II/III CRC.
The fact that elderly patients obtained no significant
benefits from adding oxaliplatin indicated that singe-
agent chemotherapy could apply to elderly patients [6].
Compared with intravenous chemotherapy of 5-Fu/Lv,
oral administration of capecitabine can remarkably en-
hance flexibility and compliance, contributing to a higher
participation rate for the elderly patients. The major
challenge, especially for elderly patients, is to balance the
survival benefits and impaired QoL caused by toxic and
side effects. Considering the final results of the X-ACT
trial, Twelves et al. [16] found that patients who experi-
enced fewer toxic and side effects had worse outcomes,
implying that dose reduction of capecitabine might com-
promise the efficacy. Thus far, no published data have
identified the long-term efficacy and tolerance of the
low-dose strategy.
For capecitabine, the dose of 1,000 mg/m2 bid is pre-
scribed frequently in clinical practice and has been reported
to be active and well tolerated among elderly patients with
breast cancer [17, 27]. Although the response rate was
assessed, no long-term results of survival data have been
reported for those patients with breast cancer. As for CRC,
the low-dose strategy was used in the AVEX trial (Clinical-
Trials.gov identifier NCT00484939) for elderly patients
with metastatic CRC; however, no comparative analysis
about long-time efficacy of this strategy compared with the
approved strategy has been published so far. Considering
the current gap, we designed this LC-ACEC trial. If our re-
sults find compromised long-term efficacy of the low-dose
strategy, it might not be an optimal dose for elderly patients
with stage II/III CRC although it is widely used at present.
Notably, previous studies reported ethnic differences in
the tolerance of capecitabine. Haller et al. [28] found that
East Asian patients had better tolerance of 5-Fu/capecita-
bine compared with Caucasian patients. An early study in-
dicated that the thymidylate synthase (TYMS) gene 3R/3R
variants were more common in Asians [29], and this could
affect 5-Fu tolerance. For the elderly Asian patients, how-
ever, the pilot Korean study did not observe a satisfactory
completion rate for the 1,250 mg/m2 dose despite better
tolerance for Asians [19]. As for China, a single-arm study
including 58 elderly (more than 65 years old) patients with
metastatic CRC showed that low-dose capecitabine was
well tolerated by those patients [30]. However, that study
was limited by the lack of data regarding efficacy and the
small sample size. In general, current evidence on the dose
of capecitabine for the elderly group of patients is
insufficient.
It is worth mentioning that our trial still has limita-
tions. The blinding is limited by the open-label nature of
the trial. In addition, time of follow-up is relatively short
to achieve long-term outcome given the loss rate caused
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our trial includes only Chinese patients and this to some
degree limits the applicability to other ethnicities
because of inter-ethnic differences in tolerance for cape-
citabine. In summary, the LC-ACEC trial is the first
randomized controlled trial to investigate the efficacy
and safety of the low-dose capecitabine adjuvant chemo-
therapy (1,000 mg/m2 bid) in elderly patients with stage
II/III CRC. If non-inferiority of the low-dose strategy is
verified, this can be recommended as a new standard
capecitabine adjuvant chemotherapy strategy, specifically
for the large group of elderly patients with stage II/III
CRC, and this is not only cost-effective but also benefi-
cial for their QoL. The result of this trial will provide
evidence on a more specific adjuvant chemotherapy
strategy for elderly patients with stage II/III CRC.
Trial status
This trial was initiated in January 2015 and is currently
recruiting patients.
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